Subsequently, other gene fusion partners to ALK were identified; EML4 is the most common of these, and ALK-rearrangements are found in 4–7% of non-small cell lung cancer (NSCLC) patients, mostly in younger patients with light or nonsmoking history and adenocarcinoma histology [2,3]. Here, EML4 is linked to non-small cell lung carcinoma.